Gå direkt till huvudinnehållet

Bronkiektasier

Senast uppdaterad: Publicerad:
Sakkunnig:
  1. Nicotra MB, Riveera M, Dale AM, et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995;108:955-61. PubMed  
  2. Clinical Evidence freelance writers. Bronchiectasis. Clin Evid 2003; 9: 1641-4. PubMed  
  3. Cole PJ. Inflammation: a two-edged sword - the model of bronchiectasis. Eur J Respir Dis Suppl 1986; 147: 6-15. PubMed  
  4. ten Hacken NHT, Wijkstra PJ, Kerstjens HAM. Treatment of bronchiectasis in adults. BMJ 2007; 335: 1089-93. PubMed  
  5. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277-84. PubMed  
  6. Mysliwiec V, Pina JS. Bronchiectasis: the ‘other' obstructive lung disease. Postgrad Med 1999;106:123-31. PubMed  
  7. Bronchiectasis and other bronchial abnormalities. In Fraser RS, Müller NL, Colman N, Paré PD, eds. Diagnosis of Diseases of the Chest, pp 2265-97. Philadelphia: W.B. Saunders Company, 1999.
  8. Crockett AJ, Cranston JM, Latimer KM, Alpers JH. Mucolytics for bronchiectasis (Cochrane Review).In: The Cochrane Library, issue 1, 2001. Oxford: Update Software. The Cochrane Library  
  9. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev, issue 1, 2002. The Cochrane Library  
  10. Franco F, Sheikh A, Greenstone M. Short acting beta-2 agonists for bronchiectasis. Cochrane Database Syst Rev, issue 3, 2003. The Cochrane Library  
  11. Sheikh A, Nolan D, Greenstone M. Long-acting beta-2-agonists for bronchiectasis. Cochrane Database Syst Rev, issue 4, 2001. The Cochrane Library  
  12. Lasserson T, Holt K, Evans D, Greenstone M. Anticholinergic therapy for bronchiectasis. Cochrane Database Syst Rev, issue 4, 2001. The Cochrane Library  
  13. Steele K, Greenstone M, Lasserson JA. Oral methyl-xanthines for bronchiectasis. Cochrane Database Syst Rev, issue 1, 2001. The Cochrane Library  
  14. Kolbe J, Wells A, Ram FSF. Inhaled steroids for bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 4, 2002. Oxford: Update Software. The Cochrane Library  
  15. Tsang KW, Tan KC, Ho PL, Ooi GC, Ho JC, Mak J, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005; 60: 239-43. PubMed  
  16. Lasserson T, Holt K, Greenstone M. Oral steroids for bronchiectasis (stable and acute exacerbations). Cochrane Database Syst Rev, issue 4, 2001. The Cochrane Library  
  17. Corless JA, Warburton CJ. Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis. Cochrane Database Syst Rev, issue 4, 2000. The Cochrane Library  
  18. Jones AP, Rowe BH. Bronchopulmonary hygiene physical therapy for chronic obstructive pulmonary disease and bronchiectasis. Cochrane Database Syst Rev, issue 2, 2000. The Cochrane Library  
  19. Jones A, Rowe BH. Bronchopulmonary hygiene physical therapy in bronchiectasis and chronic obstructive pulmonary disease: a systematic review. Heart Lung 2000; 29: 125-35. PubMed  
  20. Corless JA, Warburton CJ. Surgery vs non-surgical treatment for bronchiectasis. Cochrane Database Syst Rev, issue 4, 2000. The Cochrane Library  
  21. Dogan R, Alp M, Kaya S, Ayrancioglu K, Tastepe I, Unlu M, et al. Surgical treatment of bronchiectasis: a collective review of 487 cases. Thorac Cardiovasc Surg 1989; 37: 183-6. PubMed  
  22. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis. Cochrane Database Syst Rev, issue 4, 2003. The Cochrane Library  
  23. Cymbala AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, Victory JM, et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005; 4: 117-22. PubMed  
  24. Lin HC, Cheng HF, Wang CH, Liu CY, Yu CT, Kuo HP. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med 1997; 155: 2024-9. PubMed  
  25. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162: 481-5. PubMed  
  26. Orriols R, Roig J, Ferrer J, Sampol G, Rosell A, Ferrer A, et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999; 93: 476-80. PubMed  
  27. Keistinen T, Saynajakangas O, Tuuponen T, et al. Bronchiectasis: an orphan disease with a poorly-understood prognosis. Eur Respir J 1997;10:2784-7. PubMed  
  • Lennart Hansson, med dr och överläkare, Lung- och allergikliniken, Skånes universitetssjukhus

Tidigare sakkunniga

  • Hasse Melbye, specialist i allmänmedicin, försteamanuens vid Institutt for samfunnsmedisin, Universitetet i Tromsø
  • Leif Bjermer, professor i lungsjukdomar, Norges teknisk-naturvitenskapelige universitet, Trondheim